BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Leukemia & Lymphoma Society | Discovery Grant Program
DTSTART;VALUE=DATE:20240918
DTSTAMP:20260406T111600Z
UID:23d5185aa4f5cf72af7fae44e63fed06a0998e112f61c4b08e3fc760
CATEGORIES:Call for proposal
DESCRIPTION:Aim:  The Leukemia & Lymphoma Society\, Inc. (LLS) funds rese
 arch on leukemia\, lymphoma\, myeloma\, and all other rare blood cancers. 
 The LLS aims at funding the best science to bring better treatments to pat
 ients with every form of blood cancer.\n\nThe Discovery Grant Program (DGP
 ) is a research award program designed to encourage basic research\, techn
 ological innovation\, and informatics pipeline development. It aims at sup
 porting cutting edge\, innovative research that is discovery oriented\, co
 ncerned with understanding blood cancer properties and vulnerabilities and
  aimed toward advancing treatments for blood cancers.\n\nExamples of proje
 cts of potential interest include:\n\n	cellular activities that underlie t
 he behavior and vulnerabilities of blood cancer cells including phenomena 
 or processes such as clonal evolution\, autophagy\, unique metabolic vulne
 rabilities\, inflammation/inflammasomes\, DNA damage responses\, organella
 r changes\, and poorly understood cellular regulatory mechanisms\n	resista
 nce mechanisms including immune evasion\, resistant clone evolution and ce
 llular changes underlying development of resistance to chemotherapies\n	no
 vel biomarkers or techniques to detect and monitor blood cancer developmen
 t and progression\n	blood cancer cell interactions with the microenvironme
 nt and with the immune system\, including exploration of novel immune syna
 pses\n\nProjects NOT supported:\n\n\n	clinical trials or correlative studi
 es associated with clinical trials\n	development of a drug or treatment th
 at already has shown proof of concept\n	research that is primarily confirm
 atory or minimally incremental\n	research into cellular behavior\, mechani
 sms or development not in the context of blood cancer\n	studies of normal 
 hematopoiesis\n\nFunding:       up to $750\,000\n\nDuration:    
   3 years\n\nEligibility:    The program welcomes applications from US 
 citizens and non-US citizens\, as well as applicants who are performing re
 search outside the United States. Applicants must hold a PhD\, MD\, DVM\, 
 or equivalent degree. Applicants must be independent investigators affilia
 ted with a non-profit institution at the time funding commences and for th
 e duration of the award. Further\, they must be established investigators\
 , defined as having more than 3 years in an independent faculty appointmen
 t at the time of the Letter of Intent.\n\nHow to Apply: The 2-stage applic
 ation process begins with a Letter of Intent\, to be submitted on the LLS 
 Research Portal (create account here). LOIs should provide brief descripti
 ons of how the goals and/or approaches are novel and innovative\, and what
  impact the research may have on blood cancer. All LOIs will be reviewed f
 or eligibility\,  relevance and responsiveness to the goals of the progra
 m. Those judged to be the most promising will be invited to submit a full 
 application.  At the full application stage\, an Institutional signature 
 is required\; please contact the Research Office for this step.\n\nDeadlin
 e:      Letter of Intent: 18 September\, 2024. 3pm ET\n       
                  Notification of full application invite:
  January 2025\n                        Full Applica
 tion: 03 March 2025 (3PM ET)\n                      
   Award start: 01 October 2025\n\n\nFurther information\n\n\n	More infor
 mation about the program\, guidelines\, and instructions are available her
 e\n	The application portal can be found here\n	For any other questions\, p
 lease contact the Research Office\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR